but retatrutide is being talked about as the next big weight loss peptide. a Victorian Government health warning over the weekend has linked products sold as 'Retatrutide' to six cases of acute Retatrutide Promises Big Weight Loss,
Description
Future of Retatrutide Dosing Because Retatrutide is still in Phase 3 clinical trials, there is not yet an FDA-approved dosing protocol
BMJ Open 2021;11(2):e044711
Acute kidney injury (AKI) is a risk highlighted in FDA labels for these medications, particularly during episodes of severe dehydration from gastrointestinal symptoms
Subject to eligibility requirements and approval
FDA standards
The CANVAS trial confirmed the same result with the use of canagliflozin [103], as did the DECLARE TIMI trial where dapagliflozin was used [104]
